-
Suzhou Novoprotein Lists on Shanghai’s STAR Market for R&D Expansion
•
Suzhou Novoprotein Scientific Co., Ltd, a China-based provider of protein technology and application solutions, has successfully completed its initial public offering (IPO) on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The net proceeds from the IPO will be used to advance the company’s capabilities in diagnostics raw materials and…
-
Rainmed Medical’s caFFR System Receives TGA Approval for Coronary Disease Diagnosis
•
China-based Rainmed Medical Limited has announced that it has received market approval from Australia’s Therapeutic Goods Administration (TGA) for its in-house developed coronary angiography-based fractional flow reserve system (caFFR System). The approval marks another significant milestone for the company in expanding its global footprint. Product Overview and BenefitsThe caFFR System…
-
NeuShen Therapeutics Closes $20M Series Pre-A Financing for CNS Drug Development
•
NeuShen Therapeutics has announced the successful closure of a $20 million Series pre-A financing round led by Lapam Capital. The proceeds will be used to advance the company’s central nervous system (CNS) drug research and development platform, as well as to support the development of new drugs targeting CNS disorders.…
-
Zelgen Files NDA for Jacktinib to Treat Myelofibrosis in China
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has filed a New Drug Application (NDA) with the National Medical Products Administration (NMPA) for its JAK inhibitor, jacktinib, to treat medium to high risk myelofibrosis (MF). This includes primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post PV MF), and…
-
Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results
•
China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24 billion ($311.2 million) in revenue during the first half of this year, up 15.3% year-on-year (YOY). Product sales increased 10% YOY to RMB 2.04 billion ($283.4 million), driven by Tyvyt (sintilimab), a programmed death-1 (PD-1)…
-
Lepu Biotechnology’s MRG003 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
•
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation for its core product MRG003 in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). The epidermal growth factor receptor (EGFR) targeted antibody drug conjugate (ADC) had previously obtained Orphan Drug…
-
Lepu Biotechnology’s PD-1 Inhibitor HX008 Gains New Indication Approval
•
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its HX008, a programmed death 1 (PD-1) targeted humanized IgG4 monoclonal antibody (mAb). The drug, which was first approved in China in July this year for…
-
Neurophth Biotechnology Doses First Patient in Phase III Trial for NR082
•
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that the first patient has been dosed in a Phase III clinical study for its NR082 (rAAV2-ND4, NFS-01). The study is being conducted in China to evaluate the efficacy and safety of NR082, a recombinant adeno-associated virus serotype 2 (rAAV2), in…
-
Bio-Thera Solutions Completes Phase I Study for COVID-19 Antibody BAT2022
•
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced the completion of all dosage groups (from 100 mg to 1500 mg) in a Phase I clinical study for its BAT2022. The results of the study demonstrated good safety across all dosage groups. BAT2022: Drug OverviewBAT2022 is a bispecific neutralizing antibody against COVID-19…
-
Allergan Aesthetics Opens Shanghai Innovation Center for Medical Aesthetics
•
Allergan Aesthetics, a division of AbbVie, has officially opened its Shanghai innovation center, marking a significant expansion into the Chinese market. The center will focus on medical aesthetics education and product clinical application training, further solidifying Allergan Aesthetics’ commitment to advancing the field of aesthetic medicine. Center’s Focus and ObjectivesThe…
-
Biosyngen to Establish Cell Therapy GMP Facility in Singapore
•
Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at developing the company’s immunotherapy assets to address unmet needs in cancer treatment. The facility will serve as a base for advancing Biosyngen’s pipeline of innovative therapies. Facility Details and Strategic ImportanceThe 1,300-square-meter facility, located in…
-
Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges
•
China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85 billion ($395 million) in revenue during the first half of this year, down 3.4% year-on-year (YOY). Net profits fell 23% YOY to RMB 297 million ($41.1 million). The results reflect ongoing market challenges and policy…
-
Parexel Opens Clinical Study Supply Chain Center in Suzhou
•
US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply chain operation center in Suzhou, Jiangsu Province, China. This new facility will provide critical and ancillary supplies and laboratory logistics services for clinical trials in the Asia Pacific region. Global Network and ServicesThe Suzhou center…
-
Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has been dosed in a Phase I clinical study (ABSK043-101) for its in-house developed oral programmed-death ligand 1 (PD-L1) inhibitor, ABSK043, in patients with advanced solid tumors in China. The drug has previously completed multiple dose…
-
Arctic Vision Enrolls First Patient in Phase III Study for ARVN002
•
China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a Phase III clinical study assessing the efficacy and safety of ARVN002 (atropine sulfate) for arresting myopia progression. The study is being conducted in China and marks a significant step forward in the development of this…
-
3D Medicines Partners with Denfo Medical for Cancer Therapy Development
•
China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group, focusing on the research and development (R&D) and commercialization of novel cancer therapies. The collaboration will also cover cancer chroniclization management and novel drug services. Denfo Medical will leverage its interconnected, digitalized, and intelligent online…
-
Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278
•
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with Spain-based Almirall S.A. (BME: ALM), granting Almirall exclusive development and commercialization rights to the autoimmune disease drug candidate SIM0278 outside of Greater China. Under the terms of the deal, Almirall will pay Simcere an upfront…
-
Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion
•
Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured an undisclosed amount of funding in a Series D+ financing round. The round was led by existing investor Sherpa Healthcare Partners, with additional contributions from Taiping Fund Management, Triwise Capital, and Far East Horizon, as…
-
Santen Pharmaceutical Launches New Plant Construction in Suzhou
•
Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu Province, China. The 126,000 square meter site is designed to enhance local production capacity for prescription eye drops, anticipating increased demand from the globally aging population. The facility is expected to begin operations in 2025.…
-
Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Carvykti (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adults with relapsed or refractory multiple myeloma. The approval is limited to…
